Topics

Dova to be acquired by rare disease specialist Sobi in nearly $1B deal

05:11 EDT 1 Oct 2019 | SmartBrief

Swedish Orphan Biovitrum, also known as Sobi, will acquire Dova Pharmaceuticals through a deal valued at up to $915 million.  -More

Original Article: Dova to be acquired by rare disease specialist Sobi in nearly $1B deal

NEXT ARTICLE

More From BioPortfolio on "Dova to be acquired by rare disease specialist Sobi in nearly $1B deal"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...